<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02611453</url>
  </required_header>
  <id_info>
    <org_study_id>18285</org_study_id>
    <nct_id>NCT02611453</nct_id>
  </id_info>
  <brief_title>Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP</brief_title>
  <official_title>CO2 Cholangiography as an Alternative to Iodinated Contrast in Endoscopic Retrograde Cholangiopancreatography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carbon dioxide (CO2) gas is widely used for luminal insufflation during endoscopic retrograde
      cholangiopancreatography (ERCP) of the biliary tract. While frequently observed during
      routine ERCP, there are few data on the topic of &quot;air&quot; or &quot;CO2&quot; cholangiography. Our primary
      aim is to compare radiographic cholangiograms in patients with biliary tract disease (from
      stones or strictures) during ERCP obtained by using carbon dioxide as the contrast medium vs.
      conventional iodinated contrast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been recommended that endoscopic retrograde cholangiopancreatography (ERCP) be
      performed using carbon dioxide (CO2) instead of room air as the infused &quot;air&quot; or gas for
      luminal insufflation for reasons of improved patient comfort and in case of procedural
      adverse events (as CO2 is more quickly absorbed by the body and as it can be exhaled via the
      lungs). Air cholangiograms are often incidentally visible on fluoroscopy (radiographically)
      during ERCP prior to injection of iodinated contrast into the biliary tree. Despite the
      information from an air cholangiogram being readily available in many instances, biliary
      endoscopists and radiologists who read the fluoroscopic images taken during ERCP do not
      usually comment or interpret the &quot;air&quot; or &quot;CO2&quot; cholangiograms. Consequently, very little
      data is available on the topic of &quot;air&quot; or &quot;CO2&quot; cholangiography. As a contrast medium for
      cholangiography, CO2 might be safer than iodinated contrast, which is the standard contrast
      medium used during ERCP, as iodinated contrast cannot be easily absorbed by the body and as
      it can be trapped proximal to obstructing biliary stones or strictures and lead to biliary
      tract infection.

      This is a prospective cohort study that will enroll patients undergoing ERCP for suspected
      choledocholithiasis and/or biliary stricture(s). If they did not participate in this study,
      these patients would still require an ERCP with CO2 used as the endoscopically insufflated
      &quot;air&quot; medium. Enrolled patients will undergo an initial cholangiogram with CO2 (injected into
      the bile ducts) utilizing both conventional fluoroscopy and digital subtraction fluoroscopic
      imaging, followed by conventional cholangiography using iodinated contrast (injected into the
      bile ducts). Digital subtraction fluoroscopic imaging is a commercially available setting on
      certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast
      medium. Findings on CO2 cholangiography will be compared to those obtained from
      pre-procedural abdominal imaging along with the cholangiogram done using iodinated contrast
      at the time of the ERCP procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success of CO2 cholangiography vs. iodinated contrast</measure>
    <time_frame>Intraprocedural/immediate (during ERCP)</time_frame>
    <description>For choledocholithiasis: correct identification of the number and location of stones. For biliary strictures: correct identification of number and location of strictures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success of digital subtraction fluoroscopy vs. traditional fluoroscopy (while using CO2 as the contrast medium)</measure>
    <time_frame>Intraprocedural/immediate (during ERCP)</time_frame>
    <description>For choledocholithiasis: correct identification of the number and location of stones. For biliary strictures: correct identification of number and location of strictures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation usage/exposure of CO2 cholangiography using conventional fluoroscopy or digital subtraction fluoroscopy vs. iodinated contrast</measure>
    <time_frame>Intraprocedural/immediate (during ERCP)</time_frame>
    <description>Fluoroscopy/radiation usage/exposure will be measured for each imaging modality and then compared</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Choledocholithiasis</condition>
  <condition>Bile Duct Diseases</condition>
  <condition>Bile Duct Carcinoma</condition>
  <arm_group>
    <arm_group_label>Single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will undergo endoscopic retrograde cholangiopancreatography (ERCP) that is indicated for suspected or confirmed choledocholithiasis or biliary strictures. &quot;Air&quot; contrast cholangiography using carbon dioxide gas will be performed with standard fluoroscopy and digital subtraction fluoroscopic image capture followed by routine cholangiography using iodinated contrast and standard fluoroscopy. Carbon dioxide (CO2) is routinely used in ERCP procedures and would flow into the biliary tree of patients at the time of ERCP, irrespective of this study's interventions. Digital subtraction image capture is a commercially available setting on certain fluoroscopy units that optimizes resolution with air or CO2 used as a contrast medium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>&quot;Air&quot; contrast cholangiography using carbon dioxide gas</intervention_name>
    <description>Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).</description>
    <arm_group_label>Single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older

          -  Patients with choledocholithiasis, benign biliary strictures, malignant biliary
             strictures

          -  Biliary pathology suggested or confirmed by imaging with abdominal ultrasonography, CT
             scan, MRI/MRCP scan, or endoscopic ultrasonography (EUS)

        Exclusion Criteria:

          -  Pregnancy (self reported)

          -  Presence of cholangitis before ERCP

          -  Prior history of surgery on the stomach or duodenum that precludes conventional ERCP
             or prior biliary tree surgery (not including cholecystectomy)

          -  Failure to selectively cannulate the bile duct

          -  Life expectancy less than 30 days

          -  Prisoners

          -  Patients unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Y. Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael B. McCabe, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew Y. Wang, MD</last_name>
    <phone>434-924-1653</phone>
    <email>ayw7d@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel S. Strand, MD</last_name>
    <phone>434-243-2718</phone>
    <email>dss7a@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Y Wang, MD</last_name>
      <phone>434-924-1653</phone>
      <email>ayw7d@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel S Strand, MD</last_name>
      <phone>434-243-2718</phone>
      <email>DSS7A@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Y Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael B McCabe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel S Strand, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhang R, Zhao L, Liu Z, Wang B, Hui N, Wang X, Huang R, Luo H, Fan D, Pan Y, Guo X. Effect of CO2 cholangiography on post-ERCP cholangitis in patients with unresectable malignant hilar obstruction - a prospective, randomized controlled study. Scand J Gastroenterol. 2013 Jun;48(6):758-63. doi: 10.3109/00365521.2013.779745. Epub 2013 Apr 29.</citation>
    <PMID>23621432</PMID>
  </reference>
  <reference>
    <citation>Pisello F, Geraci G, Modica G, Scium√® C. Cholangitis prevention in endoscopic Klatskin tumor palliation: air cholangiography technique. Langenbecks Arch Surg. 2009 Nov;394(6):1109-14. doi: 10.1007/s00423-009-0548-y. Epub 2009 Aug 26.</citation>
    <PMID>19707784</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2015</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Andrew Y Wang, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>choledocholithiasis</keyword>
  <keyword>ERCP</keyword>
  <keyword>cholangiography</keyword>
  <keyword>biliary stricture</keyword>
  <keyword>bile ducts</keyword>
  <keyword>carbon dioxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choledocholithiasis</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Bile Duct Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

